



## Directorate change

October 24, 2023  
RNS Number : 0376R  
Renalytix PLC  
24 October 2023

### Renalytix plc ("Renalytix" or the "Company")

#### Directorate change

**LONDON and SALT LAKE CITY** - October 24, 2023 - [Renalytix plc](https://www.renalytix.com) (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA authorized artificial intelligence (AI) enabled blood test to assess risk of progressive kidney function decline for individuals with type 2 diabetes and early-stage chronic kidney disease, announces that Timothy Scannell has stepped down from his role as independent Non-Executive Director of Renalytix effective as of October 18, 2023, to pursue other opportunities.

**James McCullough, CEO of Renalytix plc, commented:** *"It has been a wonderful learning experience to work alongside Tim for the past 18 months. He has been a significant contributor to Renalytix, and I would like to thank him for all his efforts on the Board."*

#### *For further information, please contact:*

##### **Renalytix plc**

James McCullough, CEO

[www.renalytix.com](https://www.renalytix.com)

**Via Walbrook PR**

##### **Stifel (Nominated Adviser, Joint Broker)**

Alex Price / Nicholas Moore / Nick Harland / Samira  
Essebiyea

**Tel: 020 7710 7600**

##### **Investec Bank plc (Joint Broker)**

Gary Clarence / Shalin Bhamra

**Tel: 020 7597 4000**

##### **Walbrook PR Limited**

Paul McManus / Alice Woodings

**Tel: 020 7933 8780** or [renalytix@walbrookpr.com](mailto:renalytix@walbrookpr.com)

Mob: 07980 541 893 / 07407 804 654

##### **CapComm Partners**

Peter DeNardo

**Tel: 415-389-6400** or [investors@renalytix.com](mailto:investors@renalytix.com)

#### **About Renalytix**

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit [www.renalytix.com](https://www.renalytix.com).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOANKNBQBBDBKKB